Week In Review: Junshi Signs $1.1 Billion Deal For US-Canada Rights To PD-1
February 06, 2021 at 12:55 PM EST
Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio in an agreement worth up to $1.1 billion. Syapse closed a $68 million growth equity investment led by China's Ally Bridge Group
